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Background. Cardiac-committed cells and biomimetic scaffolds independently improve the 
therapeutic efficacy of stem cells. This study tested the long-term effects of their combination. 
Methods and Results. Eighty immune-deficient rats underwent permanent coronary artery ligation. 
Five to 7 weeks thereafter, those with an echocardiographically-measured ejection fraction (EF) ≤55% 
were reoperated on and randomly allocated to receive a cell-free fibrin patch (n=25), a fibrin patch 
loaded with 700,000 human embryonic stem cell (ESC) pre-treated to promote early cardiac 
differentiation  (SSEA1+ progenitors [n=30]) or to serve as sham-operated animals (n=25). Left 
ventricular function was assessed by echocardiography at baseline and every month thereafter until 4 
months. Hearts were then processed for the assessment of fibrosis and angiogenesis and a 5-
component heart failure score was constructed by integrating the absolute change in left ventricular 
end-systolic volume (LVESV) between 4 months and baseline, and the qPCR-based expression of 
natriuretic peptides A and B, myosin heavy chain 7 and periostin. All data were recorded and analyzed 
blindly. The cell-treated group consistently yielded better functional outcomes than the sham-operated 
group (p=0.002 for EF; p=0.01 for LVESV). Angiogenesis in the border zone was also significantly 
greater in the cell-fibrin group (p=0.006) which yielded the lowest heart failure score (p=0.04 vs 
sham). Engrafted progenitors were only detected shortly after transplantation; no grafted cells were 
identified after 4 months. There was no teratoma either. 
Conclusion. A fibrin scaffold loaded with ESC-derived cardiac progenitors results in sustained 
improvement of contractility and attenuation of remodelling without sustained donor cell 
engraftment. A paracrine effect, possibly on innate reparative responses, is a possible 
mechanism for this enduring effect. 
 
Introduction  
At least, two important lessons can be drawn from the multiple cardiac stem cell therapy reported so 
far. The first is that regardless of whether the transplanted cells directly generate a new myocardial 
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tissue or, more likely, act by harnessing  endogenous repair pathways to induce host-derived 
regeneration,1 the most effective seem those committed to a cardiac lineage.2,3 In this setting, along 
with mesenchymal stem cells exposed to a cocktail of cardiopoietic factors prior to transplantation4 
and cardiospheres,5 pluripotent stem cells are attractive because of their intrinsic capacity to be 
differentiated in any lineage, including the cardiomyogenic one, in response to appropriate cues.6 The 
second  important lesson is that conventional needle-based intramyocardial injections have several 
limitations, including random distribution of cells, stress-induced cell damage7 and, possibly, 
induction of arrhythmias.8,9 Since cardiac surgery provides the unique opportunity of a direct control 
over the heart, several studies have assessed the effects of replacing multiple intramyocardial 
injections by the epicardial delivery of a cellularized patch and, overall, their results support the 
superiority of the latter approach with regard to cell survival,10-13 reduction of fibrosis,12-14  increase in 
angiogenesis12-14  and improvement of function.10, 12-15 Additional advantages of the patch-based 
approach include strengthening of the infarcted wall which may contribute to limit adverse 
remodelling 16 and provision of a template for cells to proliferate and secrete their own matrix to which 
they can anchor.15 Among the diverse materials that can be used, fibrin is attractive because of its 
multiple advantages which include biocompatibility, suitability for cell adhesion,17 possibility to act as 
a reservoir for controlled-release growth factors18 and a long-standing safety record when used as an 
hemostatic sealant in surgery.19 
The present study was therefore designed to leverage these data by combining the use of human 
embryonic stem cell (ESC)-derived cardiac progenitors with their incorporation into a fibrin scaffold 
and to assess the outcome of such a composite construct in a rat model of myocardial infarction 






Eighty female Nude rats (Charles River) weighing an average of 200–250 g were used in this study. 
All procedures were approved by our institutional Ethics Committee and complied with the European 
legislation (European Commission Directive 86/609/EEC) on animal care.     
Experimental protocol  
Myocardial infarction was created as described previously14. Five to 7 weeks after myocardial 
infarction, rats underwent a baseline echocardiographic assessment of left ventricular (LV) function 
and all those with an ejection fraction (EF) ≥55% were excluded. The remaining rats were reoperated 
on by a median sternotomy and randomly allocated to receive a cell-free fibrin patch (n=25) or a fibrin 
patch loaded with 700,000 ESC-derived SSEA-1+ progenitors (n=30). The patch was delivered onto 
the clearly visible akinetic area and secured to the epicardium by three 6/0 polypropylene sutures. 
Twenty-five additional rats assigned to a sham group only underwent the open-chest placement of 
similar sutures, without any other procedure. No medical treatment for heart failure was given. Three 
additional rats receiving a progenitor cell-loaded fibrin patch were used for an early post-
transplantation (1, 2 and 7 days) histological assessment. 
Preparation of the SSEA-1+ progenitors 
The progenitors were derived from the I6 ESC line (generously provided by J. Itskovitz and M. Amit, 
Technion Institute, Haïfa, Israël) according to a a relatively simple growth factor-based protocol 
attempting to recapitulate signalling events involved in embryonic cardiogenesis20-22 (detailed in the 
Supplementary Material online section). This protocol allowed to reproducibly generate a population 
of SSEA-1-positive early cardiac progenitors, primarily expressing Isl-1, a transcription factor for both 
the first and second heart fields23 but also additional genes characteristic of different developmental 
stages of cardiogenesis.24 The cardiomyocyte-oriented fate of this population has previously been 
confirmed in vivo in a nonhuman primate model of myocardial infarction.25 
 
Preparation of the fibrin patch 
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Seven-hundred thousand SSEA-1-positive progenitors were first added to 150 µL of a solution made 
of fibrinogen (20 mg/mL) and α-MEM medium (Macopharma, Tourcoing, France) in an agarose-
coated Petri dish. Four units of thrombin were then added as evenly distributed 25-µL droplets of an 
equivalent volume of culture medium supplemented with thrombin to induce polymerization of the 
gel, which occurred in less than 10 minutes (at 37°C). Both fibrinogen and thrombin were components 
of the Evicel® kit (Ethicon Biosurgery, Omrix Biopharmaceuticals-Ethicon Biosurgery, Rhode Saint 
Genèse, Belgium). Previous studies in the laboratory have shown that this fibrinogen-thrombin ratio is 
appropriate to generate mechanically robust patches with good handling and suturability 
characteristics and well-preserved cell viability. 
Assessment of left ventricular function 
Left ventricular function was assessed by echocardiography at baseline and every month thereafter 
until sacrifice at 4 months, as described previously14 (more details are available in the Supplementary 
Material online section). 
Histological and immunohistochemical analyses 
Four months following the sham or transplantation procedures, rats were euthanized and sacrificed. 
Explanted hearts were processed for the determination of fibrosis and angiogenesis. In separate 
experiments, tracking of cell fate was performed one day and one week after transplantation using 
immunostaining against lamin A/C (all procedures detailed in the Supplementary Material online 
section) and completed, at 4 months only, by the search for human-specific Alu sequences by RT-
PCR. 
Relative quantification of gene expression by real-time PCR 
Total RNA was extracted from heart tissue samples using TRIzol® lysis reagent (Life Technologies, 
Saint-Aubin, France) and TissueLyser II system (Qiagen France SAS, Courtaboeuf, France) following 
the manufacturers’ instructions. Real-time PCR was performed using LightCycler 480® (Roche 
Diagnostics, France) as described in the Supplementary Material online section. 
Assessment of a heart failure index 
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In 20 randomly selected hearts (n=7, 7 and 6 for sham-operated, control acellular fibrin patches and 
cell-treated patches, respectively), a whole set of functional and PCR data were available. This cohort 
was therefore used for generating a 5-component heart failure score including the absolute change in 
LV end-systolic volume (ESV) between 4 months and baseline, and the qPCR-based expression of 
natriuretic peptides A and B, myosin heavy chain 7 and periostin. 
Statistics 
Data are summarized using mean (IC95%) or mean (SEM) values. Survival between groups was 
compared using the log-rank test and Kaplan Meier curves were plotted. Within each group, LV 
function variables measured at baseline and at 4 months were compared using paired Student tests. 
Across groups, the changes of LV function variables between repeated assessment (baseline, 1, 2, 3 
and 4 months) were compared using a linear mixed model analysis. The mean percentages of fibrosis 
and angiogenesis were compared between groups using analysis of variance. Pairwise comparisons 
were done and p-values were adjusted for multiple testing (Tukey adjustment). The “heart failure 
index” was constructed by standardizing the 5 components on the overall population (= computing z-
score for each variable) and then averaged them. Comparisons of this index between groups were 
made using analysis of variance (Tukey adjustment for multiple testing). For all analyses, a two-tailed 
p-value <0.05 was considered statistically significant. 
Analyses were conducted using SAS 9.4 (Statistical Analysis System, Cary, NC, USA). 
 
RESULTS  
Characteristics of the transplanted SSEA1+ cell population. 
Following immunomagnetic sorting, the purity rate of the SSEA-1-positive cell population was 92.5% 
± 2.6%. The transcriptomic profiling of this population, as assessed by Affymetrix microarray 
analysis, showed the down-regulation of pluripotency-associated genes like SOX2, SOX21, NANOG, 
HESX1, LEFTY, ZIC3 (Figure 1A), as compared with undifferentiated I6 ESC and this pattern was 
mirrored by the upregulation of cardiac mesoderm-committed genes like HAND1, ISL1, EOMES, 
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HAPLN1, BMP4, PKP2 (Figure 1B). Based on that same transcriptomic analysis, the SSEA-1-
negative cell fraction was also characterized by a switch-off of most pluripotency genes (Figure 1A).  
Four hours after sorting, a time point selected to match the timing by which the patch would be 
effectively delivered onto the heart, less than 10% of the SSEA-1-positive scaffold-embedded cells 
were found apoptotic, as shown by TUNEL staining and caspase-3 expression (data not shown), while 
markers suggestive of a cardiomyogenic lineage like Isl-1 were identified (Figure 2, upper panel). 
Moreover, the ability of the SSEA-1-positive cells to keep proliferating into the fibrin scaffold was 
demonstrated by Ki67 staining (Figure 2, lower panel). 
Left ventricular function assessment. 
After exclusion of rats with preserved LV functions (LVEF ≥ 55%), baseline LVEF did not differ 
between the three groups: 47.46% [95%CI:45.28%;49.63%], 47.68%  [45.96%;49.40%], and 47.37% 
[44.97%;49.77%], in sham-operated (n=18), control (n=19) and treated (n=20) hearts, respectively . 
Over the 4-month follow-up period, the death rate did not significantly differ among the three groups 
(12, 13 and 14 deaths in the sham, control and treated groups, respectively; Figure 3A) which let a 
total of 41 surviving animals (13 sham-operated rats, 12 controls and 16 treated rats) meeting the pre-
set inclusion criterion (LVEF ≤55%) available for the last 4-month echocardiographic assessment. 
Over this 4-month follow-up period, the patterns of changes remained fairly consistent within each 
group (Figure 3B). Function remained stable in the sham group in which the LVEF, at 4 months, was 
48.45% (44.71%;52.18%); it slightly increased in the control acellular fibrin group (50.36% 
[47.29%;53.42%]) and to a still greater extent in the cell-treated group (53.19% [50.10%;56.29%], 
p=0.002 vs sham). When data were expressed as the absolute difference between the baseline value 
and the 4-month final study point, LVEF was found to have increased by 0.09%±0.99% (mean±SEM) 
in sham-operated hearts, 2.36%±0.80% in control cell-free fibrin-treated hearts (p=0.014 vs baseline), 
and 5.68%±1.29% in cell+fibrin-treated hearts (p=0.0005 vs baseline). 
Left ventricular end-diastolic volumes (LVEDV) were likewise similar at baseline between the three 
groups: 344.81μL (95%CI:319.38;370.23), 365.12μL (328.88;401.35), 357.63μL 
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(95%CI:323.89;391.37) in sham, control and treated hearts, respectively. However, the patterns of 
changes were then markedly different (Figure 3C). Volumes steadily increased to a similar extent in 
the sham and control groups (absolute difference between 4 months and baseline: 44.68 μL±20.83μL; 
p=0.053 and 50.27μL±25.95μL, p=0.07 respectively) whereas the LV dilatation was much less 
pronounced in the treated group (absolute difference between 4 months and baseline: 4.64μL±24.07 
μL, p=0.85).  Patterns of changes in LV end-systolic volumes (LVESV) still more clearly delineated 
between-group differences (Figure 3D) as they increased in the sham and control groups (absolute 
difference between 4-month and baseline values: 28.08μL±14.65μL and 15.41μL±13.36μL, 
respectively), whereas they decreased by 16.76μL±15.55μL in hearts receiving the cell-loaded fibrin 
patch (p=0.013 vs sham; p=0.052 vs controls). 
The functional efficacy of epicardially delivered SSEA-1-positive progenitors was partially supported 
by real-time PCR analysis, which demonstrated a reduced expression of the stress-induced beta-
myosin heavy chain genes, atrial natriuretic factor, brain natriuretic peptide and periostin in the treated 
group as compared to sham (data not shown). When these PCR data were combined with LVESV 
changes to generate a 5-component heart failure index (Figure 4), the highest score was seen in the 
sham-operated group (2.24±1.29). It was lower in control hearts (-0.74±0.84) and further decreased in 
the treated group (-1.75±0.84, p=0.04 vs sham). 
Histological and immunohistochemical analyses. 
The extent of fibrosis did not significantly differ between the three groups (Figure 5A). Conversely, 
angiogenesis in the border zone was significantly greater in the cell+fibrin group (p=0.006 vs sham, 
Figure 5B). At the 4-month time point, there was no teratoma  in 6 hearts treated with the cell-loaded 
fibrin patch which were specifically examined for this complication. Lamin A/C-positive human cells 
were detected by immunostaining one day after transplantation in the patch implantation area 
(Supplemental Figure 1) but could no longer be found after one week. Based on this result, we 
reasoned that the probability for cells to persist at 4 months was extremely small and therefore used 
PCR rather than immunostaining to sensitize their tracking in 6 cells+fibrin-treated hearts, taking 7 
sham-operated hearts and 7 acellular fibrin patch-grafted hearts as controls. Three primers were used 
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for probing different regions of the human-specific Alu DNAsequence but, as expected, there was no 
detectable signal with either primer at this late time point in any heart tissue sample (comprising both 
the area of patch implantation and the nongrafted underlying myocardium). 
DISCUSSION 
The major finding of the present study is that a fibrin patch, in which ESC-derived cardiac progenitors 
have been embedded, improves pump function and limits adverse ventricular remodelling in a rat 
model of myocardial infarction and that, given the life expectancy of rats, these effects seem to be 
sustained over a reasonably long period of time. 
Cell scaffolding. 
. After having tested several materials, including scaffold-free cell sheets,14,15, 26 we selected fibrin as 
the cell matrix. In addition to its multiple above mentioned advantages, fibrin is attractive because of  
the tunability of its mechanical properties through an adjustment of the fibrinogen to thrombin ratio. 
Thus, in the present experiments, the selected ratio (20mg/mL and 4 Units/mL, respectively) allowed 
to achieve both an elasticity modulus (in the range of 6kPa) matching that reported appropriate for 
cells of the mesodermal lineage27 and a fiber network density allowing ingrowth of host-derived 
vessels (Figure 5). The choice of transplanting 700,000 progenitor cells was based on preliminary 
screening experiments but we acknowledge that upscaling this number might have increased cell 
engraftment, at least early after patch delivery, as suggested by our observation  of numerous donor 
cells inside the scaffold in a separate experiment where it was loaded with two million cells (Figure 
6).This observation matches the finding that fibrin can increase the amount of cells retained into the 
myocardium 24 hours after an intramyocardial injection.28   
Interpretation of outcomes. 
The present results demonstrate that hearts receiving the cell-free fibrin patch tended to have slightly 
better functional outcomes than the sham-operated animals, which has been previously reported with 
the use of injected fibrin alone29 and which likely reflects an angiogenic effect.,30, 31 However, 
embedding SSEA-1+ cells in the fibrin matrix further improved contractile function and stabilization 
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of remodelling as cells+fibrin-treated hearts consistently yielded higher values of LVEF (the increase 
of which between 4 months and baseline was more than two-fold higher than in the acellular fibrin 
group) but more importantly lower values of LVEDV and LVESV  compared with their cell-free 
counterparts. Although focus on EF could suggest that LV function was only moderately impaired at 
baseline (after infarction), analysis of LV volumes at the same time point shows that they were 
dramatically enlarged compared with healthy hearts,32,33 which makes the 4-month attenuation of 
remodelling yielded by the cells+fibrin patch functionally relevant, particularly if one keeps in mind 
that LVESV has been reported to be a strong predictive factor of outcome in patients following a 
myocardial infarction. 34 In keeping with these data, the cell-scaffold product also achieved the lowest 
value of the heart failure index generated by combining genomic and functional end points associated 
with heart failure,35 cardiomyopathy36 and adverse LV remodelling.37 Overall, these results are 
consistent with those previously reported with the use of fibrin used either in an injectable form mixed 
with skeletal myoblasts38 or bone marrow-derived cells 28,39 or as an epicardial patch loaded with 
mouse ESC-derived BMP-2-treated cardiac progenitors40 or human hESC-derived vascular cells41 in 
rat and porcine myocardial infarct models, respectively. Compared with the latter two studies, the 
present one differs by (1) the phenotype of the cells (in Vallée’s study,40 ESC-derived cardiac 
progenitors were of mouse origin while in Xiong’s study,41 the derivatives of the human ESC were not 
cardiomyocytes), (2) the extension of follow-up to 4 months (versus 50 days and 4 weeks  in Vallée’s 
and Xiong’s studies, respectively), and (3) the fact that the tested cell-scaffold construct was 
manufactured, processed and quality-controlled under similar conditions as those used for the product 
planned for a human use. It is even possible that the beneficial effects of the fibrin material could have 
been optimized by seeding cells at the surface of the fibrin biomatrix instead of incorporating them 
into it.42  
The mechanism of the incremental benefit afforded by the cell-loaded fibrin patch remains to be 
investigated. A de novo muscularization of the infarct tissue by the grafted cells can be excluded. In 
the present study, two methods were used for tracking donor cell fate: lamin A/C protein expression 
and human Alu gene expression. As early as one week after patch implantation, lamin A/C-positive 
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cells could no longer be detected and, expectedly, were not identified either after 4 months despite the 
use of a highly sensitive PCR-based tracking method.43 With the caveat of a shorter follow-up, a 
higher survival rate has been reported with the use of a fibrin patch loaded with human hESC-derived 
vascular cells, 41 which might be related to differences in cell phenotype, processing, or timing of 
delivery. Whatsoever, the contrast, in the present experiments, between the absence of a long-term cell 
engraftment and a sustained functional benefit, similar to what has been reported with other cell 
types,44 strongly supports a cell-induced paracrine signalling initiating a cascade of self-sustained 
events. This would be consistent with an attenuation of fibrosis and the increase in angiogenesis seen 
in the treated group. Our failure to identify cells expressing both markers of proliferation (Ki67) and 
cardiac lineage (troponin I) does not necessarily rule out an additional increase in the contractile cell 
pool (by mobilization of endogenous stem/progenitors or new divisions of mature cardiomyocytes) 
which could have been missed because of the late postprocedural sampling time (4 months). This 
paracrine hypothesis is relevant to the patch-based delivery strategy as shown by the ability of a 
cardiomyocyte-containing alginate scaffold to improve postinfarction heart function even though the 
grafted cells remain insulated from the host myocardium and cannot therefore couple with them.45 
Reliance on paracrine effects has practical implications in that it leads to focus on the enhancement of 
early retention of grafted cells (rather than on their sustained survival), within a time frame matching 
the release of cell-derived biomolecules which could then paracrinally foster innate repair pathways 
before clearance of the donor cells .44 We acknowledge that we did not dissect out the molecular 
events underpinning the postulated paracrine activation of endogenous reparative responses. Indeed, 
an increasing role is attributed to exosomes as possible mediators of the cells’ paracrine effects46,47 and 
deciphering the nature of their content, particularly the miRNA profile, should help in mechanistically 
identifying the various pathways targeted by the cell-released biomolecules while providing clues for 
developing cell mimetics more suitable for large-scale clinical applications.  
An important observation was the lack of teratoma in the immunodeficient rats after 4 months. This 
likely reflects the efficiency of the selection procedure aimed at discarding the cells unresponsive to 
the cardioinstructive cues. In this study, the population of progenitors was purified by  
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immunomagnetic sorting against SSEA-1 (also called Sialyl-LewisX), a carbohydrate moiety 
expressed early during the differentiation of pluripotent ESC48 which is consistent with the fact that 
cell surface proteins incur changes in their glycosylation patterns when they transition from 
pluripotency to differentiation. The transcriptomic analysis of the purified SSEA-1-positive population 
has confirmed the down-regulation of pluripotency genes (primarily NANOG and SOX-2) which may 
still be expressed at various degrees in the residual contaminating SSEA-1-negative cells  but probably 
not to the extent that a teratoma can develop since injection of this sole fraction in immunodeficient 
mice still failed to induce teratoma formation.24 The disappearance of the cells over time may also be 
considered as an additional flail-safe mechanism.  
Limitations. 
We acknowledge several limitations of this study. First, the follow-up was not extended beyond 4 
months. However, such a duration is yet significant given the rat’s life expectancy and the stability of 
functional data, as evidenced by the serial echocardiograms, provides an encouraging signal regarding 
the maintenance of the functional benefits over time. A second limitation is that cells may not migrate 
into the myocardium. This would be an issue if the grafted cells were supposed to generate a de novo 
myocardial tissue but, indeed, is not if they act primarily by releasing a blend of factors which can be 
released from the patch towards the underlying myocardium to harness endogenous repair pathways. 
Third, we did not document the potential occurrence of arrhythmic events. However, (i) the survival 
rate of the treated rats was not different from that of sham-operated animals and although we were not 
able to determine the causes of death in each group, this indirectly argues against a substantially 
greater occurrence of cell-induced life-threatening arrhythmias, and (ii) patches have been reported to 
be less arrhythmogenic than injections.,9  Fourth, our “customized” heart failure score should be 
interpreted cautiously because it has not  been externally validated and was constructed as a post-hoc 
composite of variables; of note, however, this index was not designed to predict survival, like the heart 
failure scores commonly used in the clinics, 49 but rather to assess whether the combination of end 
points generated by different methods (echocardiography and genomics) but all relevant to heart 
dysfunction, would confirm the benefits of the cells+scaffold approach, which actually turned out to 
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be the case. Finally, no mechanistic study was done to specifically determine the causes of cell loss 
which might have been facilitated by two model-intrinsic feature : (1) an immune response related to 
the xenogenic setting of the transplantation and which cannot be excluded, even in the nude rat, and 
(2) the stress that human cells have to withstand when they are implanted in a fast-beating rodent 
heart..  
In conclusion, the present data support the functional efficacy of fibrin scaffolds harbouring ESC-
derived cardiac progenitors and provide additional evidence that a long-term cell engraftment may not 
be a prerequisite for a sustained benefit. As such, they may serve as a platform for the further 
development of cell-, cell-mimetics- or biomaterial-based strategies aimed at fostering endogenous 
reparative responses. 
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Figure 1. In vitro characterization of human embryonic stem cells (ESC)-derived SSEA-1-
positive progenitors. Expression level of selected pluripotency-associated (A) and cardiac lineage 
commitment-associated (B) genes, as assessed by a transcriptome analysis using Affymetrix 
microarrays, in SSEA-1-positive progenitors, SSEA-1-negative cells and undifferentiated pluripotent 
I6 ESC taken as the reference (100%). Data are reported as means±SEM. Heatmaps of the 
transcriptome have been previously published.24 
Figure 2. Immunolabeling of SSEA-1-positive progenitors in the fibrin patch. The upper panel 
shows that the fibrin-embedded SSEA-1-positive progenitors express the cardiac transcription factor 
Isl-1 (green fluorescence) and the proliferation-associated protein Ki67 (green fluorescence, lower 
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panel). Combined red and green fluorescence and DAPI-stained nuclei (blue) are shown in merged 
images. Note SSEA-1-positive progenitors co-stain with either Isl-1 or Ki67. Bar: 20 µm. 
Figure 3. Four-month follow-up of SSEA-1-positive progenitor-grafted hearts in comparison 
with sham and control groups. (A) Kaplan–Meier survival curves during the 4-month follow-up. 
Percentages of surviving animals, in sham (n=13 out of 25), control (n=12 out of 25) and treated (n=16 
out of 30) groups. No significant difference was observed in the survival rate between the different 
groups. Significance was analyzed with the log-rank test. (B) Changes in left ventricular ejection 
fraction (LVEF) over the 4-month follow-up period. Values are presented as percentages. * p=0.014 vs 
baseline; ** p=0.0005 vs baseline; p=0.002 vs sham. (C) Absolute changes in left ventricular end-
diastolic volume (LVEDV) over the 4-month follow-up period; * p=0.053  vs baseline. (D) Absolute 
changes in left ventricular end-systolic volume (LVESV) over the 4-month follow-up period; * 
p=0.013 vs sham; p=0.052 vs controls. Data are reported as means±SEM.  
Figure 4. Box-blot representation of the heart failure index. The absolute change in LVESV 
between 4 months and baseline and the qPCR-based expression of natriuretic peptides A and B, 
myosin heavy chain 7 and periostin were used to construct a 5-component heart failure index. The 
score yielded by the control and treated groups was calculated relative to that of the total 20-heart 
cohort. The boxes represent the lower to upper quartile range, the error bars represent the entire range, 
the horizontal bar represents the median value and dot points represent mean values. Note the 
significantly lower heart failure index in the treated group vs sham. 
Figure 5. Box-blot representation of fibrosis (A) and number of capillaries (B) in sham, control 
and treated hearts. Four months after treatment, 6-10 sections per heart were stained by Sirius red 
(fibrosis) or immunostained with a rat-specific endothelial cell antibody (to label capillaries; 7 sections 
per heart). The area of fibrosis and number of capillaries were quantified using Metamorph software 
(Universal Imaging Corporation, USA). Fibrosis was expressed as the ratio between the area of scar 
tissue to the left ventricular area. The number of capillaries was expressed as per mm2 of the infarct 
border zone. The boxes represent the lower to upper quartile range, the error bars represent the entire 
range, the horizontal bar represents the median value and dot points represent mean values. 
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Figure 6. Detection of grafted SSEA-1-positive progenitors 2 days after epicardial fibrin-patch 
delivery in a nude rat. In a separate experiment, the fibrin scaffold was intentionally loaded with a 
high number (two million) of SSEA-1-positive progenitors to optimize visualization of cell patterning 
shortly (48 hours) after epicardial patch delivery.  The cells were embedded into the fibrin patch just 
after magnetic sorting and grafted in a rnu/rnu nude rat 3 weeks after left coronary ligation. (A) 
Hematoxylin–Eosin (HE) staining shows a nice incorporation of the fibrin patch harboring the SSEA-
1-positive progenitors to the surface of the heart. Grafted cells were identified by human specific 
lamin A/C antibody (B, E, red fluorescence). Many lamin A/C positive cells still expressed the cardiac 
transcription factor Islet-1 (D, green fluorescence). Panels C and F present the merged images (C: 
lamin A/C+DAPI-stained blue nuclei; F: combined green [Isl-1]+red [lamin A/C] fluorescence). 
Arrows indicate grafted cells. Dotted lines indicate the border between the fibrin patch and the heart. 
Bar: 150 µm (A); 40 µm (B-C); 20 µm (D-F). 
Supplemental Figure 1. Early engraftment of patch-embedded cells. Presence of human cells, 
staining positively for lamin A/C,  24 hours after the delivery of the cell-loaded fibrin patch onto the 
epicardium of an infarcted rat heart. Bar: 50µm. 
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Supplementary Materials 
Preparation of the SSEA-1+ progenitors 
The progenitors were derived from the human embryonic stem cell (ESC) line I6 generously provided 
by J. Itskovitz and M. Amit (Technion Institute, Haïfa, Israël). Following amplification onto irradiated 
human fibroblasts in Nutristem ™ (Biological Industries, Kibbutz Beit-Haemek, Israel), cells were 
committed towards a mesodermal-cardiac lineage by reverting the medium to α-Minimum 
Essential Medium Eagle (MEM) solution (Macopharma, Tourcoing, France) enriched with 2% insulin-
free B27 supplement (Invitrogen, Life Technologies, Carlsbad, CA), Bone Morphogenetic Protein 
(BMP)-2 (Dibodermine alpha, 10 ng/mL, marketed as InductOs® [Wyeth pharmaceuticals, now part of 
Pfizer, New York, NY]) and a fibroblast growth factor receptor (FGFR)-specific tyrosine kinase 
inhibitor, SU-5402 (1µM; Merck, Whitehouse Station, NJ). This specification phase lasted for 4 days, at 
the completion of which cells were immunomagnetically sorted after labeling with a microbead-coupled 
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anti-SSEA-1 antibody (Miltenyi, Teterow, Germany). The collected SSEA-1-positive cell yield was 
checked for its purity (percentage of SSEA-1-positive cells, as assessed by flow cytometry) and a full 
transcriptomic analysis of the parent undifferentiated I6 ESC, their SSEA-1-positive progeny as well as 
the SSEA-1-negative fraction was performed using the AffymetrixGeneAtlasTM system coupled to the 
new Human Genome U219 array (BIOAlternatives, Gencay, France). Heatmaps representative of this 
transcriptomic profiling have been previously published 24 and only the most salient data are presented 
in Figure 1A and B.  
Assessment of Left ventricular function 
Left ventricular function was assessed by echocardiography at baseline and every month thereafter 
until the sacrifice at the 4-month study point as described previously.14 Briefly, transthoracic 
echocardiography (Sequoia 516, Siemens, Seine-St.Denis, France) was performed with a 15 MHz 
transducer in animals sedated with 2 % isoflurane. Parasternal long and short axis views were obtained 
with assessment of LV end-diastolic (EDV) and end-systolic (EDS) volumes using the biplane area-
length method [(8/3π) x (LVarea2/LVlength)]. Ejection fraction was then calculated as (LVEDV-
LVESV)/(LVESV)x100. All measurements were made in triplicate and averaged by an investigator 
blinded to the treatment group. 
Histological and immunohistochemical analyses 
Four months following the sham or transplantation procedures, rats were euthanized and sacrificed. 
Explanted hearts were rinsed in PBS, immediately fixed with Shandon Cryomatrix (Thermo Scientific, 
Illkirch, France) and frozen in -196 °C nitrogen. Blocks were stored at -80 °C until they were sliced in 
7 µm-cryosections using a cryostat (CM 1850, Leica, Wetzlar, Germany). Vascularisation was 
assessed in 23 hearts (n=8, 7 and 8 for sham-operated, control acellular fibrin patches and cell-treated 
patches, respectively), in both the border zone of the infarct and in remote normal myocardium by 
immunostaining against rat endothelial cell antigen (RECA, Serotec, Oxford, UK). After exposure to 
the RECA antibody (diluted 1:30 in PBS-NHS 7 %) for 30 min, sections were incubated 30 min with a 
biotin-labelled anti-mouse antibody (Vector Laboratories Inc., Burlingame, CA 94010, USA) and 
preformed avidin-biotin peroxidase complexes (ABC/PO-solution, Vectastain ABC, Vector Labs 
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Inc.), each for 30 min. A freshly prepared peroxidase substrate solution containing 3,5-
diaminobenzidine (DAB, DAKOCytomation) allowed visualization of RECA by oxidation. After a 
final wash step, slides were counterstained with hematoxylin and mounted with FaramountTM 
(DAKOCytomation each). The blood vessel density was expressed as vessels/mm2 and 7 sections (in 
the infarct and border zones) per heart were examined. 
Fibrosis was measured by Sirius Red staining in 22 hearts (n=7, 7 and 8 for sham-operated, control 
acellular fibrin patches and cell-treated patches, respectively) and, on average, 6 to 10 sections per 
heart were examined. After fixation of tissue sections with formaldehyde (10 min), slides were rinsed 
with water before incubation with Sirius Red solution (0.1 %, 30 min, BDH Chemicals, Poole, UK). 
Nuclei were counterstained by hematoxyline (30 sec) and slides were mounted with Eukitt (Kindler, 
Freiburg, Germany). The detection of human cells entailed the use of a monoclonal anti-human lamin 
A/C antibody (dilution 1/300; Novocastra, A.Menarini, Rungis, France). Furthermore, six hearts were 
specifically examined for the search of a teratoma. Photographs were taken using a Leica DM2000 
microscope (Leica, Wetzlar, Germany) coupled to a Quicam CCD camera (Qimaging Corp., Surrey, 
BC, Canada). Results were distinguished from autofluorescence by checking all three filters. Data 
were collected using QCapture software, QCam Driver DLL version 1.73.0 (Qimaging Corp.) and 
quantified using Metamorph Offline Version 6.3r.2 (Molecular Devices, Sunnyvale, CA).  
Relative quantification of gene expression by qPCR 
Total RNA was extracted from heart tissue samples using TRIzol® lysis reagent (Life Technologies, 
Saint-Aubin, France) and TissueLyser II system (Qiagen France SAS, Courtaboeuf, France) following 
the manufacturers’ instructions. Extracted RNA was spectrophotometrically quantified using 
NanoDrop 2000 (Thermo Fisher Scientific, Saint Herblain, France). From 1000 ng of extracted RNA, 
the first-strand cDNA was then synthesized using the RevertAid First Strand cDNA Synthesis Kit 
(Thermo Fisher Scientific) with anchored-oligo(dT)18 primer and according to the manufacturer's 
instructions using Light Cycler 480 system (Roche Diagnostics, Meylan, France). The reaction was 
carried out in duplicate for each sample in a 6-µl reaction volume containing 3 µl of SYBR Green 
Master Mix, 500 nM each of the forward and reverse primers and 3 µl of diluted (1:25) cDNA. The 
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thermal profile for SYBR Green qPCR was 95°C for 8 min, followed by 40 cycles at 95°C for 15 s, 
60°C for 15 s and 72°C for 30 s. To exclude PCR products amplified from genomic DNA, primers 
were designed to span one exon-exon junction. Primer sequences used in this study are available on 
request. The gene expression stability of B2m, Actb, Hprt1 and Nubp1 were calculated using geNorm 
software and after analysis only Nubp1 and Actb were used as the references transcripts. Data were 
collected and analyzed using the LightCycler® 480 software release 1.5.0 (Roche). 
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